Comparative effects of cilostazol and other therapies for intermittent claudication.

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Many patients with peripheral arterial disease (PAD) have intermittent claudication or problems with ambulation and mobility. Exercise and smoking cessation are primary therapies for claudication, but drug treatment may provide additional benefit. The data supporting use of pentoxifylline for claudication are weak, and pentoxifylline is not generally accepted as efficacious. Cilostazol is a new drug for the treatment of claudication. It appears to modestly benefit walking ability and it has other potentially useful effects, including inhibition of platelet aggregation and beneficial effects on serum lipids. In a randomized, prospective, double-blind trial examining walking ability in patients with PAD with moderate-to-severe claudication, cilostazol was superior to both placebo and pentoxifylline.

Original languageEnglish (US)
JournalThe American journal of cardiology
Issue number12 A
StatePublished - Jun 28 2001
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Comparative effects of cilostazol and other therapies for intermittent claudication.'. Together they form a unique fingerprint.

Cite this